Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | RECQL | P46063 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | THPO | P40225 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL29810038 | 1.00 | CA1 (0.50) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL29516726 | 0.84 | ALOX15 (0.59) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL50533 | 0.84 | ALOX15 (0.59) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL413926 | 0.84 | CA1 (0.50) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL29516921 | 0.82 | MAPT (0.60) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL49885 | 0.76 | ALOX15 (0.59) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL29538557 | 0.76 | ALOX15 (0.59) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL18159499 | 0.75 | KDM4E (0.57) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL29435413 | 0.73 | ALOX15 (0.73) | CA1CA2CA4CA6KDM4E | |
| Dopamine SCHEMBL29740423 | 0.73 | KDM4E (0.59) | CA1CA2CA4CA6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 875 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113908274-B | Method for promoting dissociation of organic small molecule ligand and dopamine receptor | 中国人民解放军军事科学院国防科技创新研究院 | 2022-10-11 | — | — | CN | claimed |
| CN-113908274-A | Method for promoting dissociation of organic small molecule ligand and dopamine receptor | 中国人民解放军军事科学院国防科技创新研究院 | 2022-01-11 | — | — | CN | claimed |
| CN-111569089-A | Compound of D5R-polyamino glycoside gene vector and application thereof | 中国医学科学院医学实验动物研究所 | 2020-08-25 | — | — | CN | claimed |
| US-20190317105-A1 | Method of Identifying Transmembrane Protein-interacting Compounds | OMEROS CORP (US) | 2019-10-17 | — | — | US | claimed |
| EP-2709647-B1 | WATER SOLUBLE MEMBRANE PROTEINS AND METHODS FOR THE PREPARATION AND USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2019-08-07 | — | — | EP | claimed |
| US-20180267051-A1 | Method of Identifying Transmembrane Protein-interacting Compounds | OMEROS CORPORATION | 2018-09-20 | — | — | US | claimed |
| US-20170336418-A1 | Method of Identifying Transmembrane Protein-interacting Compounds | OMEROS CORP (US) | 2017-11-23 | — | — | US | claimed |
| EP-2073013-B1 | Method of identifying transmembrane protein-interacting compounds | OMEROS CORP (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150377896-A1 | Method of Identifying Transmembrane Protein-interacting Compounds | OMEROS CORPORATION | 2015-12-31 | — | — | US | claimed |
| US-20130084581-A1 | Method of Identifying Transmembrane Protein-Interacting Compounds | OMEROS CORPORATION (US) | 2013-04-04 | — | — | US | claimed |
| US-20050287602-A1 | Transfecting a eukaryotic cell with nucleotide sequence, contacting cell with a candidate compound; determining distribution of expressed protein in cell by detecting the distribution of detectable moiety in cell | OMEROS CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1495330-A1 | METHOD OF IDENTIFYING TRANSMEMBRANE PROTEIN-INTERACTING COMPOUNDS | O'Dowd, Brian, F. (CA) | 2005-01-12 | — | — | EP | claimed |
| US-20040014939-A1 | Novel protease gene | YOKOTA HIROSHI (JP) | 2004-01-22 | — | — | US | claimed |
| WO-2003087836-A1 | METHOD OF IDENTIFYING TRANSMEMBRANE PROTEIN-INTERACTING COMPOUNDS | O'DOWD BRIAN F (CA) | 2003-10-23 | — | — | WO | claimed |
| EP-1311251-A2 | USE OF DOPAMINE D2/D3 RECEPTOR AGONISTS TO TREAT FIBROMYALGIA | Holman, Andrew J. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020068097-A1 | Treatment for irritable bowel syndrome and related conditions | ANCILE PHARMACEUTICALS | 2002-06-06 | — | — | US | claimed |
| WO-2002005797-A2 | USE OF DOPAMINE D2/D3 RECEPTOR AGONISTS TO TREAT FIBROMYALGIA | HOLMAN ANDREW J (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001089546-A2 | TREATMENT FOR IRRITABLE BOWEL SYNDROME AND RELATED CONDITIONS | ANCILE PHARMACEUTICALS, INC. (US) | 2001-11-29 | — | — | WO | claimed |
| US-6300365-B1 | ADMINISTERING NON-ERGOT DOPAMINE D.SUB.2 /D.SUB.3 RECEPTOR AGONIST OR ACID ADDITION SALT COMPRISING 3(H)-INDOLONE COMPOUND FOR THERAPY OF FIBROMYALGIA | INMEDIX, LLC | 2001-10-09 | — | — | US | claimed |
| US-6277875-B1 | FIBROMYALGIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2001-08-21 | — | — | US | claimed |